- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01220297
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Sirolimus and Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation
Study Overview
Status
Conditions
Detailed Description
To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as graft-vs-host disease (GvHD) prevention in human leukocyte antigen (HLA)-matched related donor peripheral blood stem cell (PBSC) or marrow transplantation (BMT), collectively hematopoietic stem cell transplantation (HSCT). This study will report the toxicities associated with this drug combination.
For all treatments and procedures, Study Day is based on the day of HSCT as Day 0.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
- Acute myelogenous leukemia (AML), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years
- AML, in first or subsequent remission or relapsed/refractory disease, age 51 to 60 years of age
- AML with multilineage dysplasia
- Acute lymphoblastic leukemia (ALL), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years
- ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease
- Chronic myeloid leukemia (CML), beyond 2nd chronic phase or in blast crisis
- Myelodysplastic syndrome (MDS), including World Health Organization (WHO)classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS
- MDS with poor long-term survival including myeloid metaplasia and myelofibrosis
- Myeloproliferative disorders
- High-risk non-Hodgkin lymphoma (NHL) in 1st emission
- Relapsed or refractory NHL
- Hodgkin lymphoma (HL) beyond first remission
- Males and females of any ethnic background, 2 to 60 years of age
- Karnofsky Performance Status (KPS) ≥ 70% or Lansky performance status > 70% for patients < 16 years of age.
- Related, matched-donor identified [6/6 human leukocyte antigen (HLA)-A, B and DRB1]
- Willingness to take oral medications during the transplantation period
- Ability to understand and the willingness to sign a written informed consent document
EXCLUSION CRITERIA
- Prior myeloablative allogeneic or autologous hematopoietic stem cell transplant (HSCT)
- HIV infection
- Pregnant
- Lactating
- Evidence of uncontrolled active infection
- Serum creatinine > 1.5 mg/dL or 24-hour creatinine clearance < 50 mL/min
- Direct bilirubin, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x upper limit of normal (ULN)
- Carbon monoxide diffusing capacity (DlCO) < 60% predicted (adults) OR and in-room air oxygen saturation < 92% (children)
- Left ventricular ejection fraction < 45% (adults) OR shortening fraction < 26%(children)
- Fasting cholesterol > 300 mg/dL or Triglycerides > 300 mg/dL while on lipid-lowering agents.
- Receiving investigational drugs unless cleared by the Principal Investigator (PI).
- Prior malignancies except basal cell carcinoma or treated carcinoma in-situ.
- Cancer treated with curative intent ≤ 5 years (EXCEPTION BY PI DISCRETION) (Cancer treated with curative intent > 5 years will be allowed).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Carmustine Etoposide Cyclophosphamide
Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
|
Immunosuppressant administered orally to:
Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
Other Names:
Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion.
Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight.
MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
Other Names:
For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
Other Names:
For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
Other Names:
Cyclophosphamide is a chemotherapy agent. For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg. For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg
Other Names:
|
Experimental: FTBI + Cyclophosphamide
FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
|
Immunosuppressant administered orally to:
Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
Other Names:
Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion.
Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight.
MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
Other Names:
Cyclophosphamide is a chemotherapy agent. For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg. For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg
Other Names:
For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Graft-vs-Host Disease (GvHD) (Grade 2 to 4)
Time Frame: 100 days post-transplant
|
Assessed as the incidence of grade 2 to 4 acute graft-vs-host disease (GvHD) at Day 100 post-transplant. Stage of Acute GvHD was assessed as follows.
Grade of Acute GvHD was determined as follows.
|
100 days post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute GvHD (Grade 3 to 4)
Time Frame: 100 days post-transplant
|
Assessed as the incidence of grade 3 to 4 acute GvHD at Day 100 post-transplant. Stage of Acute GvHD was assessed as follows.
Grade of Acute GvHD was determined as follows.
|
100 days post-transplant
|
Disease-free Survival (DFS)
Time Frame: 2 years
|
Assessed as survival without recurrence of disease
|
2 years
|
Overall Survival
Time Frame: 2 years
|
Overall survival is defined as time from enrollment to time of death or last follow-up, within 2 years.
|
2 years
|
Veno-occlusive Disease (VoD)
Time Frame: 100 days post-transplant
|
Assessed as the incidence of veno-occlusive disease (VoD) at 100 days post-transplant.
|
100 days post-transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Johnston, Stanford University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Hematologic Diseases
- Graft vs Host Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cyclophosphamide
- Etoposide
- Etoposide phosphate
- Mycophenolic Acid
- Sirolimus
- Carmustine
Other Study ID Numbers
- IRB-14913
- SU-09092009-3841 (Other Identifier: Stanford University)
- BMT209 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Diseases
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
University of Colorado, DenverNot yet recruitingHematologic Malignancy | Pediatric Patients | Other Hematologic ConditionUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Massachusetts General HospitalRecruiting
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
SecuraBioCompletedHematologic MalignancyUnited States, Italy
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina